**European Thyroid Journal** 

 Eur Thyroid J 2015;4(suppl 1):21–29 DOI: 10.1159/000381801

 Received: November 17, 2014 Accepted after revision: March 19, 2015 Published online: May 29, 2015

# **The Multitarget Ligand 3-Iodothyronamine Modulates β-Adrenergic Receptor 2 Signaling**

Juliane Dinter<sup>a</sup> Noushafarin Khajavi<sup>b</sup> Jessica Mühlhaus<sup>a</sup> Carolin Leonie Wienchol<sup>a</sup> Maxi Cöster<sup>d</sup> Thomas Hermsdorf<sup>d</sup> Claudia Stäubert<sup>d</sup> Josef Köhrle<sup>c</sup> Torsten Schöneberg<sup>d</sup> Gunnar Kleinau<sup>a</sup> Stefan Mergler<sup>b</sup> Heike Biebermann<sup>a</sup>

# **Key Words**

 β-Adrenergic receptors · Thyronamine · Signaling · Calcium homeostasis · Calcium channel · Human conjunctiva

# **Abstract**

**Background:** 3-lodothyronamine (3-T<sub>1</sub>AM), a signaling molecule with structural similarities to thyroid hormones, induces numerous physiological responses including reversible body temperature decline. One target of  $3-T_1AM$  is the trace amine-associated receptor 1 (TAAR1), which is a member of the rhodopsin-like family of G protein-coupled receptors (GPCRs). Interestingly, the effects of  $3-T_1$ AM remain detectable in TAAR1 knockout mice, suggesting further targets for  $3-T<sub>1</sub>AM$  such as adrenergic receptors. Therefore, we evaluated whether β-adrenergic receptor 1 (ADRB1) and 2 (ADRB2) signaling is affected by 3- $T_1$ AM in HEK293 cells and in human conjunctival epithelial cells (IOBA-NHC), where these receptors are highly expressed endogenously. **Methods:** A labelfree EPIC system for prescreening the  $3-T_1AM$ -induced effects on ADRB1 and ADRB2 in transfected HEK293 cells was used. In addition, ADRB1 and ADRB2 activation was analyzed using a cyclic AMP assay and a MAPK reporter gene assay. Finally, fluorescence  $Ca^{2+}$  imaging was utilized to delineate 3-T<sub>1</sub>AM-induced Ca<sup>2+</sup> signaling. **Results:** 3-T<sub>1</sub>AM (10<sup>-5</sup>-

J.D. and N.K. contributed equally to this work.

# **KARGER 125**

 © 2015 European Thyroid Association Published by S. Karger AG, Basel 2235–0640/15/0045–0021\$39.50/0

E-Mail karger@karger.com www.karger.com/etj

 $10^{-10}$  M) enhanced isoprenaline-induced ADRB2-mediated  $G_s$  signaling but not that of ADRB1-mediated signaling. MAPK signaling remained unaffected for both receptors. In IOBA-NHC cells, norepinephrine-induced  $Ca<sup>2+</sup>$  influxes were blocked by the nonselective ADRB blocker timolol (10 μm), indicating that ADRBs are most likely linked with  $Ca<sup>2+</sup>$  channels. Notably, timolol was also found to block  $3-T_1AM$ (10<sup>-5</sup> M)-induced Ca<sup>2+</sup> influx. **Conclusions:** The presented data support that 3-T1AM directly modulates β-adrenergic receptor signaling. The relationship between  $3-T_1AM$  and β-adrenergic signaling also reveals a potential therapeutic value for suppressing  $Ca^{2+}$  channel-mediated inflammation processes, occurring in eye diseases such as conjunctivitis.

> © 2015 European Thyroid Association Published by S. Karger AG, Basel

# **Introduction**

3-Iodothyronamine  $(3-T<sub>1</sub>AM)$  is an amine with structural similarities to thyroid hormones [1].  $3-T_1AM$  modifies several important physiological parameters in rodents (for reviews see Zucchi et al. [2] and Piehl et al.[3] ).

Heike Biebermann

 Institut für Experimentelle Pädiatrische Endokrinologie Charité-Universitätsmedizin Berlin, Augustenburger Platz 1 DE–13353 Berlin (Germany)

E-Mail heike.biebermann @ charite.de

Stefan Mergler Department of Ophthalmology, Charité-Universitätsmedizin Berlin Augustenburger Platz 1 DE–13353 Berlin (Germany) E-Mail Stefan.Mergler @ charite.de

a Institut für Experimentelle Pädiatrische Endokrinologie, <sup>b</sup> Department of Ophthalmology, and <sup>c</sup>Institut für Experimentelle Endokrinologie, Charité-Universitätsmedizin Berlin, Berlin, and <sup>d</sup> Institut für Biochemie, Molekulare Biochemie, Medizinische Fakultät, University of Leipzig, Leipzig, Germany

In vitro, the receptor target of  $3-T_1AM$  was assigned to the trace amine-associated receptor 1 (TAAR1) [4]. Interaction of  $3-T_1AM$  with TAAR1 activates the  $G_s$ /adenylyl cyclase signaling pathways [4]. Paradoxically, several 3-T1AM-induced physiological effects still persist in *mTaar1* knockout mice, suggesting further receptor targets in vivo. In this context, previous studies using turkey erythrocytes indirectly suggested β-adrenergic receptors as potential targets for thyronamines [3, 5] . Furthermore, several findings indicate that  $3-T_1AM$  binds with high affinity to the locus coeruleus [6].

 $3-T_1AM$  has been proposed to be a multitarget ligand (reviewed by Zucchi et al. [2] ), interacting also with a member of nonselective  $Ca^{2+}$  entry channels such as the transient receptor potential melastatin channel 8 (TRPM8), which is also known as menthol receptor [7] . In the eye, functional expression of TRPM8 and other thermosensitive TRP isoforms such as the TRP vanilloid 1 channel (capsaicin receptor) have been identified in corneal neurons as well as in corneal endothelial cells [8, 9]. Both are temperature-sensitive TRP channels occurring in corneal tissue layers and cells [10]. Interestingly, TRPV1, in connection with a putative modulation by thyronamines via G protein-coupled receptors (GPCRs), may be a potential drug target in reducing inflammatory symptoms in eye and conjunctiva diseases. It is known that TRPV1 can be stimulated during exposure to the same hypertonic conditions identified in tear samples obtained from dry eye patients or patients with conjunctivitis [11, 12].

 The present study was undertaken to elucidate a potential role of β-adrenergic receptor 1 (ADRB1) and 2 (ADRB2) as new targets for  $3-T_1AM$ . We also explored a putative link between 3-T<sub>1</sub>AM actions on  $Ca^{2+}$  channels and these adrenergic receptors, which are able to specifically modulate the aforementioned TRP channels. The human conjunctival epithelial cell line (IOBA-NHC) was utilized due to the increased expression of β-adrenergic receptors, which has also been observed in the conjunctiva and eye  $[13-15]$ .

# **Materials and Methods**

# *Cloning of Adrenergic Receptors*

 All full-length β-adrenergic receptors were cloned from genomic human DNA into the eukaryotic expression vector pcDps. The  $\beta_1$ - (ADRB1, NM\_000684.2) and  $\beta_2$ -adrenergic receptors (ADRB2, NM\_000024.5) were N-terminally tagged with a hemagglutinin (YPYDVPDYA) epitope. Plasmids were sequenced and verified with BigDye-terminator sequencing (PerkinElmer Inc.,

Waltham, Mass., USA) using an automatic sequencer (ABI 3710xl; Applied Biosystems, Foster City, Calif., USA).

## *Cell Culture and Transient Transfection*

 For the cyclic AMP (cAMP) assay and MAPK characterization, HEK293 cells were cultured in MEM Earle's media containing L -glutamine supplemented with 5% FBS and nonessential amino acids (Biochrom AG, Berlin, Germany) in a humidified  $5\%$   $CO<sub>2</sub>$ incubator at 37 ° C. For functional assays, transfections were performed as described previously [16] . The IOBA-NHC cell line was used as a cell model for human conjunctival epithelial cells. Cells were grown in DMEM/HAMs F12 1:1 supplemented with 10% FBS, 1 μg/ml insulin, 5 μg/ml hydrocortisone and antibiotics in a humidified 5%  $CO<sub>2</sub>$  incubator at 37°C [17].

#### *Dynamic Mass Redistribution*

HEK293 cells (500,000 cells/well) were seeded in poly-L-lysinecoated 50-ml cell culture flasks. Twenty-four hours after seeding, cells were transiently transfected using Lipofectamine™ 2000 (Life Technologies). On the next day, cells were detached using Versene solution (Life Technologies, Darmstadt, Germany) and were transferred into fibronectin-coated 384-well plates (15,000 cells/ well) and incubated for 24 h at  $37^{\circ}$ C with  $5\%$  CO<sub>2</sub>. For receptor activation, a high-throughput dynamic mass redistribution (DMR) technology (Corning<sup>®</sup> Epic<sup>®</sup> system) was used [18] to determine direct effects of 3-T<sub>1</sub>AM (Santa Cruz Biotechnology Inc., Dallas, Tex., USA; final concentration of DMSO 0.1%) on ADRB1 and ADRB2 following costimulation with isoprenaline (ISOP, Sigma Aldrich, St. Louis, Mo., USA, dissolved in  $H_2O$ ).

#### *cAMP Assay*

 $G_s$  signaling was determined by measuring cAMP in transiently transfected HEK293 cells. For control purposes, we transfected cells with empty vector. All experiments were performed in comparison to ADRB1 and ADRB2 transfection.  $3-T_1AM$  was dissolved in DMSO and used in a concentration of 0.1% for  $10^{-5}$  M 3-T1AM, which did not affect cAMP accumulation. Stimulation was performed 48 h after transfection as described previously [19] . Cells were incubated for 40 min without ligand or with  $3-T_1AM$ (final concentration of DMSO 0.1%), ISOP or norepinephrine (NorEpi; Sigma Aldrich, St. Louis, Mo., USA; both dissolved in  $H<sub>2</sub>O$ , or were costimulated with ISOP, or NorEpi and 3-T<sub>1</sub>AM, or NorEpi with 3,3',5-triiodothyronine (T<sub>3</sub>; Sigma Aldrich; dissolved in HCl final concentration of 0.01%). Intracellular cAMP accumulation was determined as previously described [19] .

# *MAPK Activation Assay*

 MAPK activation was measured using a luciferase reporter gene assay (SRE-luc) (Promega, Fitchburg, Wis., USA). HEK293 cells were cotransfected with serum response element (SRE) plasmid DNA (pGL4.33), a reporter construct containing an SRE and the firefly luciferase reporter gene, and either receptor or empty vector plasmid DNA (mock). Two days after transfection, cells were incubated for 6 h with the respective substances (ISOP, NorEpi or  $3-T_1AM$ ) in supplement-free MEM at  $37^{\circ}$ C with 5%  $CO<sub>2</sub>$ . Reactions were terminated by aspirating the media. Cells were lysed using 1× passive lysis buffer (Promega). Measurement was conducted with automatic luciferase substrate injection of 40 μl in a black 96-well plate using a Berthold Microplate Reader (Berthold Technologies GmbH & Co. KG, Bad Wildbad, Germany).



Fig. 1. EPIC technology to identify 3-T<sub>1</sub>AM effects on ADRB1 and ADRB2 signaling. HEK293 cells were transiently transfected with ADRB1 or ADRB2, and their response to ISOP and  $3-T<sub>1</sub>AM$  alone or in costimulation was measured using the label-free dynamic mass distribution assay (EPIC technology). **a** Signaling of ADRB1 followed by application of  $10^{-6}$  M ISOP with coincubation of  $10^{-6}$  M ISOP and  $10^{-6}$  M 3-T<sub>1</sub>AM in comparison to untreated cells (basal) was measured. **b** 3-T<sub>1</sub>AM stimulation in comparison to

basal level of ADRB1 was measured. **c** The basal level of ADRB2 compared to  $10^{-6}$  M ISOP or in coincubation with  $10^{-6}$  M ISOP and  $10^{-6}$  M 3-T<sub>1</sub>AM is shown. **d** Signaling was measured in cells expressing ADRB2 following incubation with  $10^{-6}$  M 3-T<sub>1</sub>AM in comparison to untreated cells. Data are represented as means ± SEM of mock-corrected response over time. Original data are shown as one representative experiment of four independent experiments performed in three technical replicates.

# *Fluorescence Calcium Measurements*

The intracellular  $Ca^{2+}$  concentration in IOBA-NHC cells was measured as previously reported [17, 19]. In brief, IOBA-NHC cells were loaded with 1 μM fura-2/AM for 30-40 min at 37°C. Fluorescence measurements were performed with a microscope (Olympus BW50WI) at room temperature using a Ringer-like solution containing 150 mm NaCl, 6 mm CsCl, 1.5 mm CaCl $_2$ , 1 mm MgCl<sub>2</sub>, 10 mM HEPES and 10 mM glucose (pH 7.4) ( $\sim$ 300 mOsM). In addition, a digital-imaging system (TILL-Photonics, Munich, Germany) and TIDA software were used (HEKA-Electronics, Lamprecht, Germany). Fura-2 fluorescence was alternately excited at wavelengths of 340 and 380 nm and emission was measured at 510 nm. The fluorescence ratio ( $f_{340\,nm}/f_{380\,nm}$ ) is a relative index of changes in  $[Ca^{2+}]_i$  [20]. Results are presented as mean traces of  $f_{340}/$  $f_{380}$  ± SEM. Measurements lasted 10 min.

#### *Statistics*

 Data are shown as means ± SEM of independent experiments as indicated in the respective figure legends. For statistical analysis, one-way ANOVA was performed with Dunnett's multiple comparisons test with a threshold of statistical significance of  $p \le 0.05$ . Student's t test was used if the values were normally distributed in accordance with the Gaussian distribution (normality test). GraphPad Prism 6.0 (GraphPad software, San Diego, Calif., USA) was chosen for data analysis. SigmaPlot software version 12.5 (Systat, San Jose, Calif., USA) was used for the creation of particular diagrams.

# **Results**

# *ADRB1 and ADRB2 Are Targets of 3-T1AM*

 Using DMR technology, we prescreened the potential effects of  $3-T_1AM$  alone and in combination with ISOP on ADRB1 and ADRB2 signaling. A robust change in DMR following stimulation with  $10^{-6}$  M ISOP for ADRB1



**Fig. 2.** 3-T<sub>1</sub>AM supplementation shows no classic signaling effects on ADRB1 and ADRB2. **a** HEK293 cells transfected with mock, ADRB1 or ADRB2 were left unstimulated or treated with  $10^{-6}$  M ISOP or  $10^{-5}$  M 3-T<sub>1</sub>AM, followed by measurement of cAMP levels. **b** Cells were cotransfected with mock, ADRB1 or ADRB2, and with SRE-luc, a reporter construct for MAPK activation. Relative light units (RLU) were then measured. Data were obtained from 3–4 independent experiments measured in at least triplicate and are means ± SEM. A one-way ANOVA against ISOP-stimulated mock was used for statistical analysis. \*\*\*  $p \leq 0.001$ .

(fig. 1a) and ADRB2 (fig. 1b) in comparison to nonstimulated cells was registered. We also investigated the direct effect of  $10^{-5}$  M 3-T<sub>1</sub>AM on ADRB1 (fig. 1c) and ADRB2 (fig. 1d). The effect of  $3-T_1AM$  on both receptors was small but statistically significant at several time points in comparison to nonstimulated cells (one-way ANOVA with a Dunnett's multiple comparisons test,  $p < 0.05$ ). In addition, the modulatory effect of  $3-T_1AM$  in the presence of  $10^{-6}$  M ISOP was examined (p < 0.05; fig. 1a, b), with a shift in DMR for both receptors demonstrated in comparison to ISOP stimulation alone.

# 3-T<sub>1</sub>AM Alone Does Not Activate G<sub>s</sub> and MAPK at *ADRB1 and ADRB2*

Stimulation of ADRB1 and ADRB2 with  $10^{-6}$  M ISOP resulted in a robust increase of ADRB1- and ADRB2 mediated  $G_s$  signaling (fig. 2a). However, a high 3-T<sub>1</sub>AM concentration of  $10^{-5}$  M was not sufficient to activate these receptors (fig. 2a). Therefore, the observed effect in DMR was not compatible with  $G_s$  activation.

 To test whether the observed signal in DMR was due to MAPK activation, stimulation of  $10^{-6}$  M ISOP or  $10^{-5}$  M 3-T<sub>1</sub>AM was performed. A slight increase in MAPK signaling for ADRB1 with ISOP was observed, which was not found to be statistically significant (fig. 2b). In addition, no increase of MAPK signaling following  $3-T_1AM$  stimulation was observed in comparison to basal levels (fig. 2b).

# *3-T1AM Modulates ISOP-Induced cAMP Signaling of ADRB2*

To determine a modulatory effect of  $3-T_1AM$  on ADRB1 and ADRB2 on ISOP-induced signaling, we performed costimulation studies with a constant concentration of ISOP  $(10^{-6}$  M) and increasing concentrations of 3-T<sub>1</sub>AM ( $10^{-10}$ – $10^{-5}$  M) in G<sub>s</sub> signaling (fig. 3).

 Coincubation of ISOP and increasing concentrations of 3-T1AM resulted in a modest effect for ADRB1, particularly at a concentration of  $10^{-7}$  M 3-T<sub>1</sub>AM (fig. 3a). The formation of cAMP at an ISOP concentration of  $10^{-6}$  M was normalized to 1 and the fold change in cAMP formation induced by  $3-T_1AM$  was indicated. A significant modulatory effect for ADRB2 signaling with a maximal enhancement of  $G_s$  signaling of twofold over mock-



**Fig. 3.** 3- $T_1AM$  modulates ISOP-induced cAMP signaling in ADRB2. **a** HEK293 cells transiently expressing ADRB1 or ADRB2 were costimulated with a concentration of  $10^{-6}$  M ISOP and increasing concentrations of  $3-T_1AM$  ( $10^{-10}-10^{-5}$  M), followed by measurement of cAMP levels. **b** Following stimulation of cells with  $10^{-4}$  M NorEpi and challenging with increasing concentrations of  $3-T_1AM$  ( $10^{-10}-10^{-5}$  M), cAMP levels were measured. **c** Using a concentration of  $10^{-4}$  M NorEpi with increasing concentrations of  $T_3$  served as a noninterfering substance in the cAMP assay at ADRB1 and ADRB2. Data are represented as means ± SEM of 4–6 independent assays performed in triplicate as mock-corrected fold change compared to the cAMP value of the respective constantly incubated substance (set as 1). Statistical significance was determined by one-way ANOVA;  $* p \le 0.05$ ,  $** p \le 0.01$  and  $*** p \le$ 0.001.



 To further analyze whether this effect is reproducible with the endogenous ligand NorEpi, we performed costimulation studies with a concentration of  $10^{-4}$  M Nor-

 3-T1AM Effects on β-Adrenergic Receptors



 $\overline{0}$ 

0.5

1.0

1.5

cAMP (fold change mock corrected)

(fold change mock corrected)

2.0

2.5

0.5

1.0

1.5

 $*$ 

cAMP (fold change mock corrected)

fold change mock corrected)

2.0

2.5

Color version available online  $3.0 - -$  ADRB1 NorEpi  $10^{-4}$  M + 3-T<sub>1</sub>AM  $\blacksquare$  ADRB2 NorEpi  $10^{-4}$  M + 3-T<sub>1</sub>AM  $-10$   $-9$   $-8$   $-7$ –6 –5 **b**  $3-T_1AM$ ,  $log [M]$  $3.0 -$  -- ADRB1 NorEpi  $10^{-4}$  M + T<sub>3</sub>  $\blacktriangleright$  ADRB2 NorEpi 10<sup>-4</sup> M + T<sub>3</sub>

Color version available online



**Fig. 4.** NorEpi and 3-T<sub>1</sub>AM-induced Ca<sup>2+</sup> entry suppressed by the nonselective ADRB blocker timolol. Changes in cytosolic free  $Ca^{2+}$ are depicted as the ratio of the fluorescence induced by the excitation wavelength at 340 and 380 nm. Reagents were added to nontransfected IOBA-NHC cells at the time points indicated by the arrows. **a** Cells were stimulated with  $10^{-6}$  M NorEpi (filled circles) and  $Ca^{2+}$  influxes were measured (n = 3) in comparison to basal

levels ( $n = 7$ , open circles). **b** Cells were incubated with  $10^{-6}$  M Nor-Epi in the presence of  $10^{-6}$  M timolol (n = 3). **c**  $10^{-6}$  M 3-T<sub>1</sub>AM (filled circles) were added to the cells, and  $Ca<sup>2+</sup>$  levels were measured (n = 3). **d** Cells were coincubated with  $10^{-6}$  M 3-T<sub>1</sub>AM and  $10^{-6}$  M timolol (n = 3). Data are represented as means  $\pm$  SEM of 3–7 experiments.  $Ca^{2+}$  baselines were recorded as controls (n = 7).

 To rule out that the modulation of signaling is an artificial result of costimulation, we repeated the experiments by costimulation of  $10^{-4}$  M NorEpi and increasing concentrations of  $T_3$  (10<sup>-10</sup>-10<sup>-5</sup> M). Only for stimulation of ADRB1 with  $3-T_1AM$  (at a concentration of 1 nM) was a significant difference compared to stimulation with NorEpi alone observed (fig. 3c).

# 3-T<sub>1</sub>AM-Induces Ca<sup>2+</sup> Influx in Human Conjunctival *Epithelial Cells*

 To ascertain whether endogenously expressed adrenergic receptors respond to  $3-T_1AM$ , we investigated IOBA-NHC cells [22] since β-adrenergic receptors are highly expressed in eye layers and cells [14, 23, 24]. It is also known that there is an association between voltagedependent  $Ca^{2+}$  channels and adrenergic receptors [25]. In addition, there is also an association between adrenergic receptors and nonvoltage-dependent  $Ca^{2+}$  channels, such as the aforementioned TRP channels which are expressed in IOBA-NHC cells [17]. As shown in figure 4a and b, a NorEpi-induced  $Ca^{2+}$  influx was blocked by the nonselective β-adrenergic receptor antagonist timolol. More specifically, stimulation with  $10^{-6}$  M NorEpi increased the fluorescence ratio  $f_{340 \text{ nm}}/f_{380 \text{ nm}}$  from 1.200 ± 0.001 to  $1.209 \pm 0.002$  ( $p \le 0.05$ ,  $n = 3$ ) at 600 s (fig. 4a), whereas the NorEpi-induced  $Ca^{2+}$  increase was clearly suppressed in the presence of  $10^{-6}$  M timolol to 1.200  $\pm$ 0.02 ( $p \le 0.05$ ; n = 3; at 600 s; fig. 4b). Similarly, extracellular application of  $10^{-6}$  M 3-T<sub>1</sub>AM increased the fluorescence ratio from  $1.199 \pm 0.001$  to  $1.210 \pm 0.002$  (p < 0.01;  $n = 3$ ; at 600 s) at 600 s (fig. 4c), which was also blocked by  $10^{-6}$  M timolol (1.199 ± 0.002; p  $\leq$  0.01; n = 3; at 600 s; fig. 4d). The effect of  $3-T<sub>1</sub>AM$  in DMR might therefore be due to an effect of endogenously expressed TRP channels and ADRB1 or ADRB2.

# **Discussion**

# *3-T1AM Targets ADRB2 and Is Involved in Regulation of Calcium Influx*

 $3-T<sub>1</sub>AM$  is an endogenous thyroid hormone derivative that activates TAAR1 (reviewed by Piehl et al. [3] ). It has been suggested that  $3-T_1AM$  is a multitarget ligand and affects further GPCRs or interacts with non-GPCR proteins [2]. In this study, DMR, cAMP assay and a MAPK activation assay were used to ascertain whether  $3-T<sub>1</sub>AM$ induced cellular signaling is linked with ADRB1 and ADRB2. Furthermore, modulation of  $Ca^{2+}$  signaling by 3-T1AM was evaluated using an IOBA-NHC cell line which has been described as a cell model for the investigation of human conjunctiva [22] , also in an electrophysiological context [12, 17].

Our studies revealed that  $3-T_1AM$  enhances  $G_s$ -mediated signaling of ISOP-stimulated ADRB2 as a modulator. This finding might be reasoned by positive allosteric effects, which means that binding of  $3-T_1AM$  enhances binding and/or agonistic signaling properties (maximum of capacity) of ISOP. This may be explained by two different scenarios. In the case of so-called off-target effects, dimers constituting two interacting receptor protomers would mutually influence one another, and binding of  $3-T<sub>1</sub>AM$  at one protomer increases the capacity for ISOPinduced signaling at the second protomer. Several examples for such a signaling (or binding) modification in GPCR dimers have been reported (for review see Smith and Milligan [26]) and ADRB2 is known to constitute dimeric arrangements [27]. In the second potential scenario of 'on-target' allosterism,  $3-T_1AM$  would bind at an allosteric receptor site and improve, by spatial rearrangements of the monomeric receptor conformation, the signaling capacity for ISOP bound in the orthosteric binding site. Such a principle scenario of two different ligandbinding sites at a GPCR monomer has been previously suggested, for example at the lutropin receptor [28] .

 Interestingly, the observed effect of signaling inhibition at higher  $3-T_1AM$  concentrations compared to lower concentrations (fig. 3) would be compatible with a twobinding site model for  $3-T_1AM$  (low and high affinity), whereby one site would have a stimulating effect and the second an inhibitory influence. Such mechanisms have been described for the  $M_3$  muscarinic acetylcholine receptor [29] or the  $\beta_1$ -adrenergic receptor [30].

 It can be also hypothesized that the effect of a decreased  $G_s$ -mediated cAMP accumulation at increasing  $3-T_1AM$  concentrations in costimulation experiments with ISOP or NorEpi (constant concentration) should be related to the activation of  $G_i$ . This would inhibit  $G_s$ -mediated signaling. It is known that β-adrenergic receptors are promiscuous for different G protein subtypes and that their differentiated activation can be dependent on the ligand variant or concentration [31] .

Furthermore, NorEpi as well as  $3-T<sub>1</sub>AM$  increased intracellular  $Ca^{2+}$  levels in IOBA-NHC cells, which could be blocked by the nonselective adrenergic receptor blocker timolol (fig. 4). This prompts the suggestion that  $3-T_1AM$  is connected with  $Ca^{2+}$ -permeable channels or intracellular store depletion processes in connection with adrenergic receptors, which was also reported in cardiomyocytes [32].

 Since regulation of body temperature is more or less conducted by temperature-sensitive receptors, we postulate that  $3-T_1AM$  somehow activates cold 'receptors' such as the aforementioned menthol receptor TRPM8. In previous studies using the same cell line, we could delineate that the 3-T<sub>1</sub>AM-induced Ca<sup>2+</sup> effect was due to TRPM8 activation since the specific TRPM8 blocker BCTC abolished the  $3-T_1AM$  effect [7]. Interestingly, timolol was observed to have the same effect, suggesting that  $3-T_1AM$ binds to ADRBs, in particular ADRB2, which in turn activates  $Ca^{2+}$  channels such as TRPM8. A first assumption might be that  $3-T_1AM$  effects are directly mediated via protein interactions between the GPCR and TRP channel (reviewed by Veldhuis et al. [33] ), or indirectly via the  $β/\gamma$ -subunits of G<sub>i/o</sub> [34], which can also be activated by the β-adrenergic receptors [31]. This hypothesis is supported by our observations in costimulation experiments (fig. 3), which might show activation of  $G_i$  at higher 3-T1AM concentrations combined with constant ISOP or NorEpi levels (and therefore inhibition of  $G_s$  signaling). In consequence, the direct 3- $T_1AM$ -mediated  $G_i$ -induced signaling should be investigated in future studies.

# *Potential Role of 3-T1AM in Conjunctival Epithelial Cells*

 The established human conjunctival IOBA-NHC cell line was used as a relevant model of ocular surface cell biology as well as for investigation of electrophysiological investigation of TRP channels [10, 17] . Notably, an association between direct interaction of  $3-T_1AM$  with TRPM8 and suppression of TRPV1 activity could be demonstrated in this cell line [7]. The results of the present study further indicate that the multitarget  $3-T_1AM$  is a modulator of ADRB2 and mediates cellular and  $Ca^{2+}$ signaling. At this point,  $3-T<sub>1</sub>AM$  appears to play a potential role in both TRPM8- and TRPV1-mediated  $Ca^{2+}$  regulation and linked biological processes.

# **Conclusions**

We demonstrate that  $3-T_1AM$ -enhances ISOP-induced ADRB2 signaling via the  $G_s$ /adenylyl cyclase pathway. This suggests that ADRB2 is a GPCR target for  $3-T_1AM$  and that  $3-T_1AM$  might also have implications for tissues expressing ADRB2 such as the lung, skeletal muscles and skin [24] . In addition, there is evidence that ADRB is linked with  $Ca^{2+}$  channels in human conjunctival epithelial cells. This conclusion is warranted since the nonselective ADRB blocker timolol had an inhibitory effect on both NorEpi- and  $3-T_1AM$ -induced  $Ca^{2+}$  increases. In summary,  $3-\overline{T_1AM}$  is a multitarget ligand and modulates ADRB-mediated signaling in human conjunctival epithelial cells. Therefore, thyronamines, in connection with ADRB, may provide novel compounds for suppressing  $Ca^{2+}$  channels such as TRPV1 since its activation is associated with inflammation processes occurring in conjunctivitis or dry eye syndrome. Our findings shed new light on the previously proposed complex spectrum of  $3-T_1AM$  action [35] and point to a diversified functional profile of  $3-T_1AM$ .

# **Acknowledgements**

 This work was supported by the Deutsche Forschungsgemeinschaft (DFG): Graduate College 1208 (Hormonal Regulation of Energy Metabolism, Body Weight and Growth) TP1 and TP3, KL2334/2-1 and DFG Priority Program SPP1629 Thyroid Trans Act BI 893/5-1, Me 1706/13-1, KO 922/16-1 and 922/17-1, STA 1265/1-1. Human conjunctival epithelial cells were a generous gift from the laboratory of Yolanda Diebold (University Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain) and kindly provided within a collaboration by Friedrich Paulsen (Institute of Anatomy II, University of Erlangen-Nuremberg, Germany).

#### **Disclosure Statement**

The authors have nothing to disclose.

#### **References**

- 1 Scanlan TS: Minireview: 3-iodothyronamine (T1AM): a new player on the thyroid endocrine team? Endocrinology 2009;150:1108– 1111.
- 2 Zucchi R, Accorroni A, Chiellini G: Update on 3-iodothyronamine and its neurological and metabolic actions. Front Physiol 2014;5: 402.
- 3 Piehl S, Hoefig CS, Scanlan TS, Kohrle J: Thyronamines – past, present, and future. Endocr Rev 2011;32:64–80.
- 4 Scanlan TS, Suchland KL, Hart ME, Chiellini G, Huang Y, Kruzich PJ, Frascarelli S, Crossley DA, Bunzow JR, Ronca-Testoni S, Lin ET, Hatton D, Zucchi R, Grandy DK: 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 2004;10:638–642.
- 5 Cody V, Meyer T, Dohler KD, Hesch RD, Rokos H, Marko M: Molecular structure and biochemical activity of 3,5,3'-triiodothyronamine. Endocr Res 1984;10:91–99.
- 6 Gompf HS, Mathai C, Fuller PM, Wood DA, Pedersen NP, Saper CB, Lu J: Locus ceruleus and anterior cingulate cortex sustain wakefulness in a novel environment. J Neurosci 2010; 30:14543–14551.
- 7 Khajavi N, Reinach PS, Slavi N, Skrzypski M, Lucius A, Strauss O, Kohrle J, Mergler S: Thyronamine induces TRPM8 channel activation in human conjunctival epithelial cells. Cell Signal 2015;27:315–325.
- 8 Mergler S, Mertens C, Valtink M, Reinach PS, Szekely VC, Slavi N, Garreis F, Abdelmessih S, Turker E, Fels G, Pleyer U: Functional significance of thermosensitive transient receptor potential melastatin channel 8 (TRPM8) expression in immortalized human corneal endothelial cells. Exp Eye Res 2013;116:337– 349.
- 9 Parra A, Madrid R, Echevarria D, del Olmo S, Morenilla-Palao C, Acosta MC, Gallar J, Dhaka A, Viana F, Belmonte C: Ocular surface wetness is regulated by TRPM8-dependent cold thermoreceptors of the cornea. Nat Med 2010;16:1396–1399.
- 10 Mergler S, Valtink M, Takayoshi S, Okada Y, Miyajima M, Saika S, Reinach PS: Temperature-sensitive transient receptor potential channels in corneal tissue layers and cells. Ophthalmic Res 2014;52:151–159.
- 11 Pan Z, Wang Z, Yang H, Zhang F, Reinach PS: TRPV1 activation is required for hypertonicity-stimulated inflammatory cytokine release in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2011;52:485–493.
- 12 Khajavi N, Reinach PS, Skrzypski M, Lude A, Mergler S: L-Carnitine reduces in human conjunctival epithelial cells hypertonic-induced shrinkage through interacting with TRPV1 channels. Cell Physiol Biochem 2014;34:790– 803.
- 13 Matsuo T, Cynader MS: Localization of  $\alpha_2$ adrenergic receptors in the human eye. Ophthalmic Res 1992;24:213–219.
- 14 Messina Baas O, Pacheco Cuellar G, Toral-Lopez J, Lara Huerta SF, Gonzalez-Huerta LM, Urueta-Cuellar H, Rivera-Vega MR, Babayan-Mena I, Cuevas-Covarrubias SA: ADRB1 and ADBR2 gene polymorphisms and the ocular hypotensive response to topical betaxolol in healthy Mexican subjects. Curr Eye Res 2014;39:1076–1080.
- 15 Neufeld AH, Zawistowski KA, Page ED, Bromberg BB: Influences on the density of β-adrenergic receptors in the cornea and iris – ciliary body of the rabbit. Invest Ophthalmol Vis Sci 1978;17:1069–1075.
- 16 Mühlhaus J, Dinter J, Nürnberg D, Rehders M, Depke M, Golchert J, Homuth G, Yi CX, Morin S, Köhrle J, Brix K, Tschop M, Kleinau G, Biebermann H: Analysis of human TAAR8 and murine Taar8b mediated signaling pathways and expression profile. Int J Mol Sci 2014;15:20638–20655.
- 17 Mergler S, Garreis F, Sahlmuller M, Lyras EM, Reinach PS, Dwarakanath A, Paulsen F, Pleyer U: Calcium regulation by thermo- and osmosensing transient receptor potential vanilloid channels (TRPVs) in human conjunctival epithelial cells. Histochem Cell Biol 2012; 137:743–761.
- 18 Schröder R, Janssen N, Schmidt J, Kebig A, Merten N, Hennen S, Müller A, Blättermann S, Mohr-Andrä M, Zahn S, Wenzel J, Smith NJ, Gomeza J, Drewke C, Milligan G, Mohr K, Kostenis E: Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol 2010;28:943–949.
- 19 Piechowski CL, Rediger A, Lagemann C, Mühlhaus J, Muller A, Pratzka J, Tarnow P, Grüters A, Krude H, Kleinau G, Biebermann H: Inhibition of melanocortin-4 receptor dimerization by substitutions in intracellular loop 2. J Mol Endocrinol 2013;51:109–118.
- 20 Grynkiewicz G, Poenie M, Tsien RY: A new generation of  $Ca^{2+}$  indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440–3450.
- 21 Frielle T, Daniel KW, Caron MG, Lefkowitz RJ: Structural basis of β-adrenergic receptor subtype specificity studied with chimeric  $\beta_1$ / β2-adrenergic receptors. Proc Natl Acad Sci USA 1988;85:9494–9498.
- 22 Diebold Y, Calonge M, Enriquez de Salamanca A, Callejo S, Corrales RM, Saez V, Siemasko KF, Stern ME: Characterization of a spontaneously immortalized cell line (IOBA-NHC) from normal human conjunctiva. Invest Ophthalmol Vis Sci 2003;44:4263– 4274.
- 23 Enriquez de Salamanca A, Siemasko KF, Diebold Y, Calonge M, Gao J, Juarez-Campo M, Stern ME: Expression of muscarinic and adrenergic receptors in normal human conjunctival epithelium. Invest Ophthalmol Vis Sci 2005;46:504–513.
- 24 Regard JB, Sato IT, Coughlin SR: Anatomical profiling of G protein-coupled receptor expression. Cell 2008;135:561–571.
- 25 Bavencoffe A, Gkika D, Kondratskyi A, Beck B, Borowiec AS, Bidaux G, Busserolles J, Eschalier A, Shuba Y, Skryma R, Prevarskaya N: The transient receptor potential channel TRPM8 is inhibited via the alpha 2a adrenoreceptor signaling pathway. J Biol Chem 2010; 285:9410–9419.
- 26 Smith NJ, Milligan G: Allostery at G proteincoupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol Rev 2010;62:701–725.
- 27 Sartania N, Appelbe S, Pediani JD, Milligan G: Agonist occupancy of a single monomeric element is sufficient to cause internalization of the dimeric  $β_2$ -adrenoceptor. Cell Signal 2007;19:1928–1938.
- 28 Heitman LH, Kleinau G, Brussee J, Krause G, Ijzerman AP: Determination of different putative allosteric binding pockets at the lutropin receptor by using diverse drug-like low molecular weight ligands. Mol Cell Endocrinol 2012;351:326–336.
- 29 Thor D, Schulz A, Hermsdorf T, Schöneberg T: Generation of an agonistic binding site for blockers of the M3 muscarinic acetylcholine receptor. Biochem J 2008;412:103–112.
- 30 Baker JG, Hill SJ: Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. Trends Pharmacol Sci 2007;28:374–381.
- 31 Wenzel-Seifert K, Seifert R: Molecular analysis of  $\beta_2$ -adrenoceptor coupling to  $G_s$ -,  $G_i$ -, and Gq-proteins. Mol Pharmacol 2000;58: 954–966.
- 32 Ghelardoni S, Suffredini S, Frascarelli S, Brogioni S, Chiellini G, Ronca-Testoni S, Grandy DK, Scanlan TS, Cerbai E, Zucchi R: Modulation of cardiac ionic homeostasis by 3-iodothyronamine. J Cell Mol Med 2009;13:3082– 3090.
- 33 Veldhuis NA, Poole DP, Grace M, McIntyre P, Bunnett NW: The G protein-coupled receptor-transient receptor potential channel axis: molecular insights for targeting disorders of sensation and inflammation. Pharmacol Rev 2015;67:36–73.
- 34 Birnbaumer L, Perez-Reyes E, Bertrand P, Gudermann T, Wei XY, Kim H, Castellano A, Codina J: Molecular diversity and function of G proteins and calcium channels. Biol Reprod 1991;44:207–224.
- 35 Gompf HS, Greenberg JH, Aston-Jones G, Ianculescu AG, Scanlan TS, Dratman MB: 3-Monoiodothyronamine: the rationale for its action as an endogenous adrenergic-blocking neuromodulator. Brain Res 2010;1351: 130–140.